T cell lymphomas are among the toughest blood cancers to treat. Immunotherapy, despite its success in many cancers, struggles ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Innate lymphoid cells, which curiously behave like T cells even though they don’t recognize specific antigens, show promise as a potential cancer therapeutic. In the years that followed, other groups ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

MSK hematologist-oncologist Dr. Lia Palomba led a clinical trial that resulted in FDA approval of lisocabtagene maraleucel (Breyanzi®), a CAR T cell therapy, for marginal zone lymphoma. Marginal zone ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...